



Record of Urgent Decision

Date: Thursday 10 December 2020

Decision taken by:

Kathryn Lavery (KL) Chairman
 Rod Barnes (RB) Chief Executive

In consultation with:

Steve Page	(SP)	Deputy Chief Executive/Executive Director Quality, Governance and Performance Assurance
Dr Julian Mark	(JM)	Executive Medical Director
Kathryn Vause	(KV)	Acting Executive Director of Finance
Nick Smith	(NS)	Executive Director of Operations
Christine Brereton	(CB)	Director of Workforce and Organisational Development
Karen Owens	(KO)	Interim Director of Urgent Care and Integration
Anne Cooper	(AC)	Non-Executive Director
Andrew Chang	(ACC)	Non-Executive Director
Jeremy Pease	(JP)	Non-Executive Director
Tim Gilpin	(TG)	Non-Executive Director
John Nutton	(JN)	Non-Executive Director
Phil Storr	(PS)	Associate Non-Executive Director

Decision recorded by:

Juliana Field (JF) Head of Corporate Affairs

National Category 3 and 4 Validation Pilot (Paper UA20.002)

In accordance with Standing Order 5.2* the following decision was taken:

- To formally support the Trusts involvement in Phase 2 of the National Category 3 and 4 Pilot from the 11 December 2020.

Prior to the decision being taken, paper UA20.003 was circulated to individuals listed above via email. Responses were received from AC, ACC, JN, JP, TG, NS, SP and KO, all of whom supported the proposal.

CERTIFIED AS A TRUE RECORD

Chairman (Kath Lavery)

Chief Executive (Rod Barnes)

**SO5.2 - Emergency Powers and Urgent Decisions*

The powers which the Board has reserved to itself within these Standing Orders (see Standing Order 2.7(5)) may in emergency or for an urgent decision be exercised by the Chief Executive and the Chairman after having consulted at least two non-officer members. The exercise of such powers by the Chief Executive and Chairman will be reported to the next formal meeting of the Board in public session for formal noting.



MEETING TITLE Trust Board Paper		DATE CIRCULATED 09/12/2020	
TITLE of PAPER	National Category 3 and 4 Validation Pilot – Phase 2	PAPER REF	UA20.003
KEY PRIORITIES	Embed an ethos of continuous improvement and innovation, that has the voice of patients, communities and our people at its heart Deliver the best possible response for each patient, first time Be a respected and influential system partner, nationally, regionally and at place		
PURPOSE OF THE PAPER	To gain formal approval from the Board to commence Phase 2 of the National Category 3 and 4 Validation Pilot from 11 th December 2020 following a successful Phase 1.		
For Approval	<input checked="" type="checkbox"/>	For Assurance	<input type="checkbox"/>
For Decision	<input checked="" type="checkbox"/>	Discussion/Information	<input type="checkbox"/>
AUTHOR / LEAD	Rob Connell Sector Commander (EOC)	ACCOUNTABLE DIRECTOR	Nick Smith Director of Operations
DISCUSSED AT / INFORMED BY On the 28 th August the Trust Board approved the Trusts involvement of YAS in the National Category 3 and 4 Validation Pilot. YAS has now been asked to take part in Phase 2 but requires Board approval for go live on the 11 th December 2020.			
PREVIOUSLY AGREED AT:	Committee/Group: Board of Directors	Date: 28 th August 2020	
RECOMMENDATION(S)	The YAS Trust Board formally support the Trusts involvement in Phase 2 of the National Category 3 and 4 Pilot from the 11th December 2020.		
RISK ASSESSMENT		Yes	No
Corporate Risk Register and/or Board Assurance Framework amended <i>If 'Yes' – expand in Section 4. / attached paper</i>		<input type="checkbox"/>	<input type="checkbox"/>
Equality Impact Assessment <i>If 'Yes' – expand in Section 2. / attached paper</i>		<input type="checkbox"/>	<input checked="" type="checkbox"/>
Resource Implications (Financial, Workforce, other - specify) <i>If 'Yes' – expand in Section 2. / attached paper</i>		<input type="checkbox"/>	<input checked="" type="checkbox"/>
Legal implications/Regulatory requirements <i>If 'Yes' – expand in Section 2. / attached paper</i>		<input type="checkbox"/>	<input checked="" type="checkbox"/>
ASSURANCE/COMPLIANCE			
Care Quality Commission Choose a DOMAIN(s)			
NHSI Single Oversight Framework Choose a THEME(s)		7. None of the above	

Category 3 and 4 Validation Project Phase 2

Background

On the 28th August the Trust Board approved the Trusts involvement in the National Category 3 and 4 Validation Pilot. YAS has now been asked to participate in Phase 2 which seeks to review and increase the number of codes which are available for validation. It is expected that this will see an increase in the benefits seen in phase 1 even further.

Phase 1 was successful and safe (with no untoward incidents or impact on performance) but involved small number of pre-determined AMPDS codes. Phase 2 will expand the number of codes included in process.

As part of the assurance process for Phase 2 we require Board approval once more before we go live on the 11th December.

Process

There are no changes to the process put in place for Phase 1 which was successful in supporting safe and efficient clinical validation.

As in phase 1 there continues to be exclusions to this process which are included in the current SOP at appendix 1 (see attachment).

Performance

Data from phase 1 of the trial has so far shown no adverse impact on response times and no patient safety issues have been identified. Data is presented bi-weekly from two other trusts who report a similar position. Since the trial the code set concerned has seen a positive impact on both Hear & Treat and See, Treat & Convey compared with weeks previous to the trial.

Requirements

All technical and system functionality has already been implemented for phase 1. Similarly all processes have been agreed and implemented in the initial phase.

As there are new codes to be entered into the trial there will need to be changes to the DCR reference tables to ensure that the new trial codes prompt to be sent to the navigator.

The change in codesets has been modelled and shows an equitable demand from incidents on the navigator. We have however increased our Clinical Advisors requirement by 1 anticipating an increase in demand from the new codeset.

Conclusion

Phase 1 of the trial was successful but was limited in scope of codesets.

Phase 2 of the trial will require only minor adjustments to Phase 1 but will increase the number of calls going for validation as part of the trial, improving patient care and experience.

The change to the codes entering the trial will represent equal or slightly increased demand for clinical input and staffing has been adjusted to take account of this. .

Recommendations

The YAS Trust Board notes the content of this paper and **approves** the Trusts involvement in Phase 2 the National Category 3 and 4 Pilot.

Phase 2 Overview and Standard Operating Procedure (SOP)



Phase 2 Summary
and SOP.docx